WO2003097634A1 - Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone - Google Patents
Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone Download PDFInfo
- Publication number
- WO2003097634A1 WO2003097634A1 PCT/JP2003/006119 JP0306119W WO03097634A1 WO 2003097634 A1 WO2003097634 A1 WO 2003097634A1 JP 0306119 W JP0306119 W JP 0306119W WO 03097634 A1 WO03097634 A1 WO 03097634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- salt
- hydrate
- compound
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a method for producing an intermediate for producing a quinoline carboxylic acid derivative having high antibacterial activity and safety, and an important production intermediate in the production method.
- quinolone carboxylic acids are widely used in medicine as synthetic antibacterial agents, but resistant bacteria and side effects are major therapeutic problems. To solve such problems, many quinolone carboxylic acid derivatives have been synthesized, and their antibacterial activity and safety have been studied.
- R w represents an amino group, a methylamino group, a hydroxyl group, a thiol group, or a hydrogen atom
- R 11 represents the following substituent
- R 12 and R 13 together form a methylene chain, forming a 3- to 6-membered ring
- A is C one X 3 (wherein, X 3 is a halogen atom, an alkyl group, an alkoxy group having 1 to 6 carbon atoms 1 or et 6 carbon atoms, triflumizole Ruo Lome Chino les group, or means a hydrogen atom) Or a nitrogen atom.
- X 1 and X 2 each independently represent a halogen atom
- Z is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxyalkyl group having 1 to 6 carbon atoms, and an alkyl group having 1 to 6 carbon atoms.
- a 2-oxo-11,3-dioxol-4-ylmethyl group or a 3-acetoxy-2-oxobutyl group is meant.
- R 14 represents a methoxy group or a chlorine atom.
- R represents a protecting group for an amino group. This definition of substituent R is irrelevant for the present invention.
- a pyrrolidine compound is substituted at the 7-position of a quinoline nucleus compound having a fluorocyclopropylamino group introduced at the 1-position to introduce a pyrrolidinyl group.
- the present invention relates to a compound (2a) which is an intermediate for producing the above quinolonecarbonic acid derivative (1) having excellent antibacterial activity and high safety.
- R 15 represents a methoxy group or a hydrogen atom.
- the present inventors have conducted extensive studies on a method for efficiently producing an intermediate (2a) for producing the quinolone carboxylic acid derivative (1). As a result, the pyrrolidine compound was reacted with the compound of the formula (3) to effect the pyrrolidine substitution. It has been found that an intermediate containing the compound (2a) can be industrially advantageously produced by introducing the group and reacting the compound (7) immediately before the ring-closing reaction for forming a quinolone ring. Was.
- R represents an aryloxy group, an aralkyloxy group, or a C 1-6
- R 1 and R 2 each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, an alkyl group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms.
- R 3 represents a hydrogen atom or an amino protecting group.
- R ′ represents an alkyl group having 1 to 6 carbon atoms
- R, RR 2 and R 3 represent Is equivalent to the definition of ]
- R, R ⁇ R 2 and R 3 are as defined above.
- R, R 1 , R 2 and R 3 are as defined above.
- a compound represented by the formula (2), wherein the compound represented by the formula is subjected to ester hydrolysis.
- R represents an aryloxy group, an aralkyloxy group, or a C 1-6
- R 1 and R 2 each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, an alkyl group having 1 carbon atom or 6 carbon atoms, or an alkoxy group having 1 carbon atom or 1 carbon atom
- R 3 represents a hydrogen atom or an amino protecting group.
- R represents an aryloxy group, an aralkyloxy group, or an alkoxy group having 1 to 6 carbon atoms
- R 1 and R 2 each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, or a carbon atom having 1 to 6 carbon atoms.
- R 3 represents a hydrogen atom or an amino-protecting group
- R ′ represents an alkyl group having 1 to 6 carbon atoms.
- R represents an aryloxy group, an aralkyloxy group, or a C 1-6
- R 1 and R 2 each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, an alkyl group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms
- 3 represents a hydrogen atom or an amino protecting group.
- Compound (2) can be produced from compound (3) by the following steps.
- R 1 and R 2 represent a hydrogen atom, a fluorine atom, a chlorine atom, an alkyl group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms. There is no particular limitation as long as it does not inhibit the reaction between (3) and the amine compound (4). Among them, R 1 is preferably a fluorine atom, and R 2 is preferably a methoxy group or a hydrogen atom.
- R 3 represents a hydrogen atom or a protecting group for an amino group.
- the protecting group for the amino group may be selected from the group consisting of an alkoxycarbonyl group, an aralkyloxycarbonyl group, an acryl group, an aralkyl group, an alkoxyalkyl group, and a substituted silyl group.
- the protecting group for these amino groups is not particularly limited as long as it does not inhibit the reaction between compound (3) and amine compound (4) and can be effectively deprotected in the production of compound (1).
- R 3 is preferably an alkoxycarbonyl group, an aralkyloxycarbonyl group, an acyl group, an alkoxyalkyl group, or a substituted silyl group, and is preferably an alkoxycarbonyl group, an aralkyloxycarbonyl group, or an acryl group. More preferred.
- Alkoxycarbonyl - as Le group from 1 to 3 halogen atoms are substituted also include good C 1 _ 6 alkoxycarbonyl group, in particular tertiary butoxycarbonyl two Le group (. B o radicals) And a 2,2,2-trichloromouth ethoxycarbyl group, and the like, and a tertiary butoxycarbonyl group is preferred.
- the aralkyloxycarbonyl group is C 7 _ 2 which may be substituted with a -6 alkoxy group or a nitro group.
- An aralkyloxycarbonyl group specifically, a benzyloxycarbonyl group (C bz group), a p-methoxybenzyloxycarbonyl group, and a p-12-port benzyloxycarbonyl group.
- a benzyloxycarbonyl group (C bz group) is preferable.
- the Ararukinore group C i 6 alkoxy group, but it may also be a nitro group and substituted C 7 - 2.
- an aralkyl group Specific examples thereof include a 1-phenylethyl group, a benzyl group, a p-nitrobenzyl group, a p-methoxybenzyl group, and a triphenylmethyl group.
- the alkoxyalkyl group, good ⁇ Rukokishi d 6 alkyl group is a halogen atom substituted, include C 3 5 cyclic ether group and the like, specifically main Examples thereof include a toxicoxymethyl group, a tertiary butoxymethyl group, a 2,2,2-trichloromouth ethoxymethyl group, and a tetrahydrofuranyl group.
- Araru Kirushiriru groups include such alkyl diphenyl silyl group, in particular trimethylsilyl group, an isopropyl dimethyl silyl group, a Examples include a tertiary butyldimethylsilyl group, a tribenzylsilyl group, and a tertiary butyldiphenylsilyl group.
- R is not particularly limited as long as it is a group capable of forming a carboxylic acid ester.
- examples of such R include an aryloxy group, an aralkyloxy group, and an alkoxy group having 1 to 6 carbon atoms. Specific examples thereof include a phenyloxy group, a benzyloxy group, a methoxy group, an ethoxy group, and a propoxy group. They may further have a halogen atom, an alkyl group or the like as a substituent.
- R it is convenient and preferable to use an alkyl group having 1 to 6 carbon atoms, and among these, a methyl group and an ethyl group are preferable.
- the step of obtaining the compound (5) will be described. This step is achieved by reacting the compound (3) with the amine compound (4).
- the amine compound (4) used may be a free base or a salt with an inorganic or organic acid. It is desirable to use one or more equivalents of the amine
- This step is preferably performed in the presence of a base. That is, in this step, HF is generated with the progress of the reaction, and this HF removes a necessary protecting group, for example, and forms a salt with the amine compound to inhibit the reaction with the compound (3). Corrosion of the reactor can be expected, and HF can cause pollution problems. In order to prevent these problems, this step is preferably performed in the presence of a base. It is preferable to use one or more equivalents of the base. When this step is carried out using an acid addition salt of compound (4), a base is required in order to make this salt a free base.
- the salts of the amine compound (4) include hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, g Salts of inorganic or organic acids such as formic, maleic and fumaric acids Can be mentioned. Further, those salts may be hydrates or solvates.
- Examples of the base used in this step include organic bases such as trimethylamine, triethylamine, and 4- (dimethylamino) pyridine, and inorganic bases such as ammonia, carbonated sodium, sodium carbonate, sodium hydroxide, and hydroxylated sodium. Although tertiary amines, in particular, triethylamine are preferred.
- the reaction solvent is not particularly limited as long as it does not inhibit the reaction, and examples thereof include acetonitrinole, N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and the like. Acetonitrile and N, N-dimethylacetamide are preferred.
- the reaction temperature can be arbitrarily selected between the freezing point and the boiling point of the reaction solution, and is preferably between room temperature and the boiling point of the reaction solution.
- the reaction time is up to the confirmation of disappearance of the raw material, but is usually 1 hour to 100 hours, preferably 1 hour to 24 hours.
- the step of obtaining the compound (6) will be described.
- the compound (5) may be reacted with an alkyl orthoformate in acetic anhydride. It is not always necessary to use the isolated and purified compound (5), but it is preferable to use the isolated and purified one. It is preferable to use at least one equivalent of alkyl orthoformate and acetic anhydride.
- the alkyl orthoformate may be one having an alkyl group having 1 to 6 carbon atoms, but ethyl orthoformate or methyl orthoformate is preferred.
- the alkyl group portion of the alkyl orthoformate is R ′ in the compound (6). That is, R ′ is preferably an ethyl group or a methyl group.
- an inorganic acid such as sulfuric acid, an organic acid such as acetic acid, or a Lewis acid such as zinc oxide may be added as a catalyst.
- the reaction solvent is not particularly limited as long as it does not inhibit the reaction, but it is preferable to use alkyl orthoformate as the solvent.
- the reaction temperature can be arbitrarily selected between the freezing point and the boiling point of the reaction solution, and is preferably between room temperature and the boiling point of the solvent.
- the reaction time is up to the confirmation of the disappearance of the raw materials, but is usually 1 hour to 100 hours, preferably 1 hour to 6 hours. It is.
- the step of obtaining the compound (8) will be described.
- the reaction may be carried out by reacting the compound (6) with the aminy conjugate (7) in a solvent in the presence of a base. It is not necessary to use the isolated and purified product (6), but it is preferable to use the isolated and purified product.
- the base examples include organic bases such as 1, dimethylamine, triethylamine, 4- (dimethinoleamino) pyridine, and inorganic bases such as ammonia, potassium carbonate, sodium carbonate, sodium hydroxide, and potassium hydroxide. But tertiary amines, especially triethylamine, are preferred! / ,.
- the amine compound (7) is an acid addition salt
- the amount of the base is equal to or more than the equivalent required to convert the amine compound (7) into a free base and the amount required to trap hydrogen fluoride generated by the reaction. It is preferable to use a base.
- the compound (7) may be in the form of an acid addition salt.
- the acid that forms such an acid addition salt may be either an inorganic acid or an organic acid.
- the inorganic acid include hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid, hydrobromic acid, and hydroiodic acid.
- the organic acid include p-toluenesulfonic acid, benzenesulfonic acid, and methanesulfonic acid (sulfonic acids, which may further have a substituent such as a halogen atom or an alkyl group. ), Trifluoroacetic acid, acetic acid, formic acid, maleic acid, or fumaric acid (carboxylic acids).
- the reaction solvent is not particularly limited as long as it does not inhibit the reaction. Examples thereof include toluene, N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulfoxide, and N-methylpyrrolidone. And toluene is preferred.
- the reaction temperature can be arbitrarily selected between the freezing point and the boiling point of the reaction solution, but is preferably room temperature.
- the reaction time is up to the confirmation of the disappearance of the raw material, but is usually 30 minutes to 24 hours, preferably 30 minutes to 6 hours.
- the step of obtaining the compound (2) will be described.
- the reaction can be carried out by reacting the compound (8) in a solvent in the presence of a base. Further, a phase transfer catalyst may coexist. It is not always necessary to use the compound (8) which has been isolated and purified, but it is preferable to use the compound which has been isolated and purified.
- the base include organic bases such as trimethinoleamine, triethynoleamine, 4- (dimethylamino) pyridine, and inorganic bases such as ammonia, potassium carbonate, sodium carbonate, sodium hydroxide, and sodium hydroxide. Among them, potassium hydroxide is preferred.
- the base is preferably used in an amount equal to or more than that required for trapping hydrogen fluoride generated during the ring closure reaction and hydrolyzing the ester.
- the base can be added directly to the reaction system or dissolved in a solvent such as water, and then added. An aqueous solution is more preferable. Also, the base or its solution need not necessarily be mixed with the reaction solvent.
- the reaction solvent is not particularly limited as long as it does not inhibit the reaction. Examples thereof include toluene, N, N-dimethylacetamide, N, N-dimethylformamide, dimethylsulfoxide, and N-methylpyrrolidone. And toluene is preferred.
- phase transfer catalyst is not particularly limited as long as it allows the reaction to proceed, but quaternary butylammonium bromide (TBAB) is preferred.
- TBAB quaternary butylammonium bromide
- the reaction temperature can be arbitrarily selected between the freezing point and the boiling point of the reaction solution, and is preferably between room temperature and the boiling point of the reaction solution.
- the reaction time is up to the confirmation of disappearance of the raw material, but is usually 1 hour to 100 hours, preferably 1 hour to 24 hours.
- compound (2) may be isolated and purified by a usual operation. That is, for example, the pH is adjusted by adding an appropriate acid to the reaction solution, and then the mixture is stirred under cooling, and the crystals of the precipitated compound (2) are collected by filtration, or an appropriate acid is added to the reaction solution. After adjusting the pH, the compound (2) is extracted by adding an appropriate extraction solvent, the extract is concentrated, and then recrystallized with an appropriate extraction solvent.
- compound (2) may be obtained as a free form or as a salt.
- salts include hydrochloric, sulfuric, nitric, hydrofluoric, hydrobromic, hydrofluoric, p-toluenesulfonic, methanesulfonic, trifluoroacetic, trichloroacetic, acetic, formic, maleic
- salts of inorganic acids or organic acids such as acids and fumaric acids
- salts of alkali metals or alkaline earth metals such as sodium, potassium, calcium, and lithium.
- compounds (2) May be obtained as a solvate in either case of a free form or a salt.
- the solvate in addition to solvates such as water, ethanol, propanol, acetonitrile, and acetone, water in the air can be obtained. And hydrates formed by absorption.
- BocHN ethyl 2,4,5-trifluoro-3-methoxybenzoinoleate acetate 5.00 g, 18.1 Ommo 1
- acetonitrile 5 OmL
- triethylamine 5.lmL, 2.0 eq
- 7- (S) -primary tert-butoxycarbonylamino-5-azaspiro [2.4] heptane 3.84 g, 1.O eq
- Example 4 7- ⁇ 7- (S) -primary tert-butoxycarbonylamino-5-azaspi-mouth [2.4] heptoh-5-yl ⁇ —6-fluoro-11- [2-(S) -fluoro— 1- (R) -cyclopropinole] 1,4-dihydro-8-methoxy 4-oxoquinoline 1-3 monorubonic acid
- [4-1- (7- (S) -Primary-butoxycarbonylamino-5-azaspiro [2.4] heptose 5-yl ⁇ -1,2,5-difluorobenzoyl-3-methoxy] acrylate (740mg, 1.34mmo1), toluene (14.8mL), 3N-potassium hydroxide (2.23mL) , 5 eq) was added with tetrabutyn
- Echinole 2,4,5-Tritrifluorobenzoyl acetate (3.00 g, 12.19 mmo 1), acetonitrile (6 OmL), triethylamine (3.4 mL, 2.0 eq) — (S)-[Tertiary butoxycarbonylamino] -5—azaspiro [2.4] heptane (3.11 g, 1.2 eq) was added, and the mixture was stirred at 40 ° C. for 23 hours. After allowing to cool, the solvent was distilled off under reduced pressure. Ethyl acetate (90 mL) was added to the residue, and the mixture was heated and dissolved at 40 ° C., and the organic layer was washed with water (30 mL ⁇ 2 times).
- Example 7 7- ⁇ 7- (S) -primary tert-butoxycarbonylamino-5-azaspi-mouth [2.4] hept-1-5-inole ⁇ -16-funoleolol 1-1 [2- (S) -funole B — 1 (R) —cyclopropyl] — 1,4 dihidro 4 oxoquinoline 3 3 rubonic acid
- the compound (2) useful as an antibacterial agent can be produced at low cost and in high yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004505367A JPWO2003097634A1 (ja) | 2002-05-17 | 2003-05-16 | キノロンカルボン酸誘導体の製造方法 |
KR1020047018477A KR101041277B1 (ko) | 2002-05-17 | 2003-05-16 | 퀴놀론카르복실산 유도체의 제조방법 |
EP03728079A EP1518856A4 (en) | 2002-05-17 | 2003-05-16 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE |
US10/510,956 US20050143407A1 (en) | 2002-05-17 | 2003-05-16 | Process for porducing quinolonecarboxylic acid derivative |
AU2003234810A AU2003234810A1 (en) | 2002-05-17 | 2003-05-16 | Process for producing quinolonecarboxylic acid derivative |
HK06100074.3A HK1080076A1 (zh) | 2002-05-17 | 2006-01-04 | 喹諾酮羧酸衍生物的製備方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002142383 | 2002-05-17 | ||
JP2002-142383 | 2002-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003097634A1 true WO2003097634A1 (fr) | 2003-11-27 |
Family
ID=29544982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/006119 WO2003097634A1 (fr) | 2002-05-17 | 2003-05-16 | Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050143407A1 (ja) |
EP (1) | EP1518856A4 (ja) |
JP (1) | JPWO2003097634A1 (ja) |
KR (1) | KR101041277B1 (ja) |
CN (1) | CN100422170C (ja) |
AU (1) | AU2003234810A1 (ja) |
HK (1) | HK1080076A1 (ja) |
RU (1) | RU2004136997A (ja) |
WO (1) | WO2003097634A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1757598A1 (en) * | 2004-05-13 | 2007-02-28 | Daiichi Pharmaceutical Co., Ltd. | Substituted pyrrolidine derivative |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097634A1 (fr) * | 2002-05-17 | 2003-11-27 | Daiichi Pharmaceutical Co., Ltd. | Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone |
JP4616770B2 (ja) * | 2003-06-19 | 2011-01-19 | 第一三共株式会社 | 選択的なアミノ置換基導入法 |
CN107513053A (zh) * | 2015-08-10 | 2017-12-26 | 江苏吴中医药集团有限公司 | 一种西他沙星水合物的制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247464A1 (en) * | 1986-05-19 | 1987-12-02 | Fujisawa Pharmaceutical Co., Ltd. | New quinolone compounds and a process for the preparation thereof |
EP0275971A1 (en) * | 1987-01-21 | 1988-07-27 | Kyorin Pharmaceutical Co., Ltd. | Process and intermediates for quinolonecaboxylic acid |
EP0347851A1 (en) * | 1988-06-21 | 1989-12-27 | Shionogi Seiyaku Kabushiki Kaisha | Quinolonecarboxylic acids |
JPH05117238A (ja) * | 1991-10-23 | 1993-05-14 | Chugai Pharmaceut Co Ltd | キノロンカルボン酸誘導体の製造方法及びその合成中間体 |
JPH06172345A (ja) * | 1992-12-10 | 1994-06-21 | Ss Pharmaceut Co Ltd | キノロンカルボン酸誘導体の製造法及びその中間体 |
JPH08198819A (ja) * | 1995-01-24 | 1996-08-06 | Hokuriku Seiyaku Co Ltd | (2,3,5−トリハロゲノ−4−メチル)ニトロベンゼン誘導体 |
JP2000319261A (ja) * | 1999-05-13 | 2000-11-21 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸類の製造方法 |
JP2001002676A (ja) * | 1999-06-24 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸誘導体の製法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY105136A (en) * | 1988-04-27 | 1994-08-30 | Daiichi Seiyaku Co | Optically active pyridonecarboxylic acid derivatives. |
WO1996023782A1 (fr) * | 1995-02-02 | 1996-08-08 | Daiichi Pharmaceutical Co., Ltd. | Composes heterocycliques |
AR027761A1 (es) * | 2000-03-31 | 2003-04-09 | Daiichi Seiyaku Co | Un derivado del acido quinolonacarboxilico, las composiciones antibacterianas que lo contienen y el uso de dicho derivado para la elaboracion de drogaspara el tratamiento de enfermedades infecciosas |
WO2003097634A1 (fr) * | 2002-05-17 | 2003-11-27 | Daiichi Pharmaceutical Co., Ltd. | Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone |
-
2003
- 2003-05-16 WO PCT/JP2003/006119 patent/WO2003097634A1/ja not_active Application Discontinuation
- 2003-05-16 EP EP03728079A patent/EP1518856A4/en not_active Withdrawn
- 2003-05-16 AU AU2003234810A patent/AU2003234810A1/en not_active Abandoned
- 2003-05-16 US US10/510,956 patent/US20050143407A1/en not_active Abandoned
- 2003-05-16 CN CNB038112558A patent/CN100422170C/zh not_active Expired - Fee Related
- 2003-05-16 KR KR1020047018477A patent/KR101041277B1/ko not_active IP Right Cessation
- 2003-05-16 RU RU2004136997/04A patent/RU2004136997A/ru not_active Application Discontinuation
- 2003-05-16 JP JP2004505367A patent/JPWO2003097634A1/ja active Pending
-
2006
- 2006-01-04 HK HK06100074.3A patent/HK1080076A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247464A1 (en) * | 1986-05-19 | 1987-12-02 | Fujisawa Pharmaceutical Co., Ltd. | New quinolone compounds and a process for the preparation thereof |
EP0275971A1 (en) * | 1987-01-21 | 1988-07-27 | Kyorin Pharmaceutical Co., Ltd. | Process and intermediates for quinolonecaboxylic acid |
EP0347851A1 (en) * | 1988-06-21 | 1989-12-27 | Shionogi Seiyaku Kabushiki Kaisha | Quinolonecarboxylic acids |
JPH05117238A (ja) * | 1991-10-23 | 1993-05-14 | Chugai Pharmaceut Co Ltd | キノロンカルボン酸誘導体の製造方法及びその合成中間体 |
JPH06172345A (ja) * | 1992-12-10 | 1994-06-21 | Ss Pharmaceut Co Ltd | キノロンカルボン酸誘導体の製造法及びその中間体 |
JPH08198819A (ja) * | 1995-01-24 | 1996-08-06 | Hokuriku Seiyaku Co Ltd | (2,3,5−トリハロゲノ−4−メチル)ニトロベンゼン誘導体 |
JP2000319261A (ja) * | 1999-05-13 | 2000-11-21 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸類の製造方法 |
JP2001002676A (ja) * | 1999-06-24 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | キノロンカルボン酸誘導体の製法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1518856A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1757598A1 (en) * | 2004-05-13 | 2007-02-28 | Daiichi Pharmaceutical Co., Ltd. | Substituted pyrrolidine derivative |
EP1757598A4 (en) * | 2004-05-13 | 2010-07-21 | Daiichi Seiyaku Co | SUBSTITUTED PYRROLIDINE DERIVATIVE |
US7977327B2 (en) | 2004-05-13 | 2011-07-12 | Daiichi Sankyo Company, Limited | Substituted pyrrolidine derivative |
US8455482B2 (en) | 2004-05-13 | 2013-06-04 | Daiichi Sankyo Company, Limited | Substituted pyrrolidine derivative |
Also Published As
Publication number | Publication date |
---|---|
US20050143407A1 (en) | 2005-06-30 |
JPWO2003097634A1 (ja) | 2005-09-15 |
KR20040106556A (ko) | 2004-12-17 |
RU2004136997A (ru) | 2005-06-27 |
CN100422170C (zh) | 2008-10-01 |
CN1653061A (zh) | 2005-08-10 |
EP1518856A4 (en) | 2006-12-13 |
HK1080076A1 (zh) | 2006-04-21 |
EP1518856A1 (en) | 2005-03-30 |
KR101041277B1 (ko) | 2011-06-14 |
AU2003234810A1 (en) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2799271B2 (ja) | 置換マレイミド類の製造方法 | |
JP5202635B2 (ja) | インテグラーゼ阻害剤の調製のためのプロセスおよび中間体 | |
JP2000512994A (ja) | テトラヒドロイミダゾキノリンアミン調製方法 | |
JP2628541B2 (ja) | 3−アルキル−3−アミノメチルピロリジン類 | |
CN111592522B (zh) | 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途 | |
JP2006232842A (ja) | 光学活性を誘発する7−ピロリジン置換体を持った光学活性のキノリンカルボン酸誘導体及びその製造方法 | |
CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
WO2003097634A1 (fr) | Procede de production d'un derive d'acide carboxylique et quinoloneprocede de production d'un derive d'acide carboxylique et quinolone | |
ES2333628T3 (es) | Procedimiento para preparar derivados de 1-halo-2,7-naftiridinilo. | |
JP5017101B2 (ja) | 不斉四置換炭素原子含有化合物の製法 | |
WO2002014277A1 (fr) | Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci | |
JP4616770B2 (ja) | 選択的なアミノ置換基導入法 | |
WO2007037303A1 (ja) | テトラ置換-5-アザスピロ[2.4]へプタン誘導体の製法およびその光学活性中間体 | |
JP4011819B2 (ja) | インドール誘導体の製造法およびその中間体 | |
CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
EP4043439A1 (en) | An improved process for the synthesis of ivacaftor [ | |
JP2002201191A (ja) | キノロンカルボン酸誘導体の製造方法およびその製造中間体 | |
JPH0714943B2 (ja) | ピリジン誘導体 | |
JPWO2004058710A1 (ja) | 新規ベンズアミド誘導体及びその製造法 | |
JPH10130232A (ja) | アゼチジノン誘導体及びその製造方法 | |
JPH0748367A (ja) | ビシクロアミン誘導体 | |
JP2001328993A (ja) | 光学活性ホスフィン化合物 | |
JP2002114765A (ja) | 3−アミノ−4−カルボニルピラゾール化合物の製造方法 | |
JP2002363171A (ja) | 4−置換−3−アミノイソオキサゾール誘導体の製法 | |
WO2002024696A1 (fr) | Procede de production de derive heterocyclique fondu tricyclique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004505367 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003728079 Country of ref document: EP Ref document number: 10510956 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018477 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038112558 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004136997 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018477 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003728079 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003728079 Country of ref document: EP |